Clinical and economic outcomes of embolic complications and strategies for distal embolic protection during percutaneous coronary intervention in saphenous vein grafts

Journal of Invasive Cardiology

Volumn 18, Issue 2, 2006, Pages 49-53

  Senter, Shaun R ^a   Nathan, Sandeep ^a   Gupta, Akshay ^a   Klein, Lloyd W ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CORONARY ARTERY BYPASS GRAFT; COST BENEFIT ANALYSIS; ECONOMIC ASPECT; EMBOLISM; EMBOLISM PREVENTION; HEART CATHETERIZATION; HEART INFARCTION; HIGH RISK BEHAVIOR; HOSPITAL COST; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; PERCUTANEOUS CORONARY INTERVENTION; PREDICTION; RISK ASSESSMENT; SAPHENOUS VEIN GRAFT; VALIDATION PROCESS;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; COHORT STUDIES; CORONARY ARTERY BYPASS; COSTS AND COST ANALYSIS; EMBOLISM; FEMALE; GRAFT OCCLUSION, VASCULAR; HEALTH CARE COSTS; HUMANS; MALE; MIDDLE AGED; PREVENTIVE MEDICINE; RETROSPECTIVE STUDIES; SAPHENOUS VEIN; TREATMENT OUTCOME;

EID: 33645972320     PISSN: 10423931     EISSN: 15572501     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Rates of PCI in 2000. http://www.cdc.gov/nchs/fastats/pdf/ad319t8.pdf. Accessed December 10, 2003.
2. DeFeyter PJ, van Suylen R, de Jaegere PPT, et al. Balloon angioplasty for the treatment of lesions in saphenous vein grafts. J Am Coll Cardiol 1993;21:1539-1549.
3. Hong MK, Mehran R, Dangas G, et al. Are we making progress with percutaneous saphenous vein graft treatment? J Am Coll Cardiol 2001;38:150-154.
4. Piana RN, Paik GY, Moscucci M, et al. Incidence and treatment of "no-flow" after percutaneous coronary intervention. Circulation 1994;89:2514-2518.
5. Klein LW, Kern MJ, Berger P, et al. on behalf of the Interventional Committee of the Society of Cardiac Angiography and Interventions. Suggested management of the no-reflow phenomenon in the cardiac catheterization laboratory. Catheter Cardiovasc Interv 2003;60:194-201.
6. Baim DS, Wahr D, George D, et al. on behalf of the Saphenous vein graft Angioplasty Free of Emboli Randomized (SAFER) Trial Investigators. Randomized trial of distal embolic protection device during percutaneous intervention in saphenous vein aorto-coronary bypass grafts. Circulation 2002;105:1285-1290.
7. Cohen DJ, Murphy SA, Baim DS, et al., for the SAFER Investigators. Cost-effectiveness of distal embolic protection for patients undergoing percutaneous intervention of saphenous vein bypass grafts: Results from the SAFER trial. J Am Coll Cardiol 2004;44:1801-1808.
8. Lefkovits J, Holmes DR, Califf RM, et al. for the CAVEAT-II Investigators. Predictors and sequelae of distal embolization during saphenous vein graft intervention From the CAVEAT-II Trial. Circulation 1995; 92:734-740.
9. Zaacks SM, Allen JE, Calvin JE, et al. Value of the American College of Cardiology/American Heart Association stenosis morphology classification for coronary interventions in the late 1990s. Am J Cardiol 1998;82:43-49.
10. Myler RK, Shaw RE, Stertzer SH, et al. Lesion morphology and coronary angioplasty: Current experience and analysis. J Am Coll Cardiol 1992;19:1641-1652.
11. Giugliano GR, Kuntz RE, Popma JJ, et al. for the Saphenous Vein Graft Angioplasty Free of Emboli Randomized (SAFER) Trial Investigators. Determinants of 30-day adverse events following saphenous vein graft intervention with and without a distal occlusion embolic protection device. Am J Cardiol 2005;95:173-177.
12. Hong MK, Popma JJ, Pichard AD, et al. Clinical significance of distal embolization after transluminal extraction atherectomy in diffusely diseased saphenous vein grafts. Am Heart J 1994;127:1496-1503.
13. Hong M, Mehran R, Dangas G, et al. Creatine-kinase-MB enzyme elevation following successful saphenous vein graft intervention is associated with late mortality. Circulation 1999;1000:2400-2405.
14. Krone RJ, Shaw RE, Klein LW, et al. on behalf of the ACC-NCDR. Evaluation of the ACC/AHA and the SCAI lesion classification system in the current "stent" era of coronary interventions (from the ACC-NCDR). Am J Cardiol 2003;92:389-394.
15. Klein LW, Brindis RG, Kutcher MA, et al. for the ACC-NCDR Registry. Intervention in saphenous vein grafts: A predictive model based on clinical presentation of 5,899 consecutive cases in the ACC-NCDR Registry. J Am Coll Cardiol 2002;39:8A.
16. Nathan S, Gupta A, Satran A, et al. Predictors of short and long-term adverse outcomes following saphenous vein graft percutaneous intervention. J Am Coll Cardiol 2003;41:47A.
17. Nathan S, Satran A, Almeda FQ, et al. Angiographic and clinical predictors of major embolic complications during percutaneous saphenous vein graft intervention. Am J Cardiol 2002;90:40H.
18. American College of Cardiology National Data Registry: Data elements and definitions. American College of Cardiology, 2003.
19. Taira DA, Seto TB, Siegrist R, et al. Comparison of analytic approaches for the economic evaluation of new technologies alongside multicenter clinical trials. Am Heart J 2003;145:452-458.
20. Consumer Price Index. ftp://ftp.bls.gov/pub/special.requests/cpi/cpiai.txt. Accessed December 12, 2004.
21. Stone GW, Rogers C, Hermiller J, et al. for the FilterWire EX Randomized Evaluation Investigators. Randomized comparison of distal protection with a filter-based catheter and a balloon occlusion and aspiration system during percutaneous intervention of diseased saphenous vein aorto-coronary bypass grafts. Circulation 2003;108:548-553.